Immune cell therapy takes on kidney disease
NCT ID NCT06469190
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new treatment called KN5501, which uses specially engineered immune cells (CAR NK cells) to target and destroy harmful B cells in people with relapsed or refractory immune nephropathy, a kidney disease caused by the immune system attacking the kidneys. The study will enroll 36 adults and primarily check for safety and side effects, while also looking at whether the treatment can control the disease. Participants will receive chemotherapy before the cell infusion to help the cells work.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Anti-CD19 CAR NK cells (KN5501) plus chemotherapy (fludarabine and cyclophosphamide)
What this could lead to
If it works, this could point toward a new treatment option for people with hard-to-treat immune kidney disease.
What could go wrong
This is a very early, small trial (36 people) focused on safety. It may not show clear benefit, and side effects from the cells or chemotherapy could be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANCA ASSOCIATED VASCULITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Changhai hospital
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••